Amneal Pharmaceuticals, Inc. (2DT.F)

5,40 +0,44 (+8,87%) Börsenschluss: 03:29PM CEST

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
https://amneal.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 7.850

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Chirag K. Patel	Co-Founder, Co-CEO, President & Director	1,59M	N/A	1967
Mr. Chintu Patel R.Ph.	Co-Founder, Co-CEO & Director	1,59M	N/A	1972
Mr. Anastasios G. Konidaris	Executive VP & CFO	967,75k	N/A	1967
Mr. Jason B. Daly Esq.	Senior VP, Chief Legal Officer & Corporate Secretary	727,9k	N/A	1974
Ms. Nikita Shah	Executive VP & Chief Human Resources Officer	793,09k	N/A	1979
Mr. Andrew S. Boyer	Executive VP & Chief Commercial Officer of Generics	1,12M	N/A	1966
Mr. Anthony DiMeo	Head of Investor Relations	N/A	N/A	N/A
Mr. Gregory Sgammato	Senior Vice President of Corporate Development	N/A	N/A	N/A
Mr. Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	N/A	N/A	N/A
Dr. Sanjay Kumar Jain Ph.D.	Chief Quality Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 3. Die grundlegenden Scores sind Audit: 2, Vorstand: 6, Shareholderrechte: 4, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.